Top Markets
#1 MarsCoin MarsCoin +37.64%
#2 Palladium Network Palladium Network +27.94%
#3 Siren Siren +26.04%
#4 Status Status +24.20%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
#6 BankrCoin BankrCoin +15.09%
#7 ICON ICON +15.04%
#8 Useless Coin Useless Coin +11.93%
#9 Ankr Network Ankr Network +11.88%
#10 Bedrock Bedrock +11.87%
Coin of the day
MarsCoin MarsCoin
Settings
Language
ENGLISH
Currency
USD
Theme
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
Rank in Stocks #18388
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Share Price
$0.28078542
Market Cap
$199.87M
Change (1 day)
-0.34%
Change (1 year)
-10.19%
Country
TW
Trade TaiGen Biopharmaceuticals Holdings Limited (4157)

Category

Healthcare
Revenue for TaiGen Biopharmaceuticals Holdings Limited (4157)
Revenue in Sep 2026 TTM: 0
According to TaiGen Biopharmaceuticals Holdings Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for TaiGen Biopharmaceuticals Holdings Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH